H
Hunan Er-Kang Pharmaceutical Co Ltd
SZSE:300267
Hunan Er-Kang Pharmaceutical Co Ltd
SZSE:300267
Price:
4.28
CNY
11.17%
Market Closed
Market Cap:
¥8.8B
Relative Value
The Relative Value of one Hunan Er-Kang Pharmaceutical Co Ltd stock under the Base Case scenario is 2.25 CNY. Compared to the current market price of 4.28 CNY, Hunan Er-Kang Pharmaceutical Co Ltd is Overvalued by 47%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
2.25
CNY
Overvaluation 47%
H
Multiples Across Competitors
Competitors Multiples
Hunan Er-Kang Pharmaceutical Co Ltd Competitors
Hunan Er-Kang Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
H
|
Hunan Er-Kang Pharmaceutical Co Ltd
SZSE:300267
|
8.8B CNY | 6.8 | -28.6 | -33.7 | -33.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
987.9B USD | 15.2 | 47.9 | 32.3 | 34.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
596.5B USD | 6.3 | 22.3 | 15.4 | 19 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
293B CHF | 4.8 | 31.2 | 13.1 | 15.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
249.7B CHF | 5.7 | 23 | 14.2 | 18.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
240.5B GBP | 5.5 | 31.7 | 17.5 | 24.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
307.4B USD | 4.7 | 16.8 | 10.5 | 12.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.4 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.9B USD | 2.5 | 20.2 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.6B USD | 2.6 | 17.8 | 7.4 | 9.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
